NMDA

CAS No. 6384-92-5

NMDA( LC488A | LC 488A | LC-488A )

Catalog No. M18940 CAS No. 6384-92-5

N-Methyl-D-aspartic acid is an amino acid that, as the D-isomer, is the defining agonist for the NMDA receptor subtype of glutamate receptors.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG 33 In Stock
50MG 47 In Stock
100MG 63 In Stock
200MG 109 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    NMDA
  • Note
    Research use only, not for human use.
  • Brief Description
    N-Methyl-D-aspartic acid is an amino acid that, as the D-isomer, is the defining agonist for the NMDA receptor subtype of glutamate receptors.
  • Description
    LC-488A is a prototypic agonist at the NMDA-type glutamate receptor that regulates ion channels; important in long-term potentiation, ischemia, and epilepsy.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    LC488A | LC 488A | LC-488A
  • Pathway
    MAPK/ERK Signaling
  • Target
    ERK
  • Recptor
    NMDA receptor
  • Research Area
    Neurological Disease
  • Indication
    ——

Chemical Information

  • CAS Number
    6384-92-5
  • Formula Weight
    147.13
  • Molecular Formula
    C5H9NO4
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : 15 mg/mL 101.95 mM;
  • SMILES
    CN[C@H](CC(=O)O)C(=O)O
  • Chemical Name
    N-Methyl-D-aspartic acid

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Cull-Candy S, et al. Curr Opin Neurobiol, 2001, 11(3), 327-335.
molnova catalog
related products
  • AZ32

    AZ32 is an orally bioavailable and blood-brain barrier-penetrating?ATM?inhibitor with an?IC50?of <6.2 nM for ATM enzyme, and an?IC50?of 0.31 μM for ATM in cell.

  • ERK-IN-4

    ERK-IN-4 is a cell-permeable ERK inhibitor with potential antiproliferative effects for the study of diseases caused by immune dysfunction.

  • AZD0364

    AZD0364 (AZD-0364) is a potent, selective, orally active ERK1/2 inhibitor for treatment of NSCLC.